This chemical is specifically designed to target and degrade PD-1 and PD-L1 proteins, which are key players in immune checkpoint pathways. By degrading these proteins, it helps to enhance the immune system's ability to recognize and attack cancer cells. This makes it a promising candidate for cancer immunotherapy, particularly in cases where tumors evade immune detection through the PD-1/PD-L1 pathway. Its application could lead to more effective treatments for various types of cancers, including melanoma, lung cancer, and others that exploit this immune evasion mechanism. Additionally, it offers a novel approach compared to traditional inhibitors, as it directly removes the target proteins rather than just blocking their function.